Global Generics Pharma Leader Selects Kneat
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 09 2025
0mins
Source: Newsfilter
Kneat's New Partnership: Kneat.com, inc. has signed a Services Agreement with a multinational generic pharmaceuticals producer to digitalize its drawing management process, enhancing efficiency and accuracy in engineering and validation workflows.
Customer Satisfaction and Growth: Kneat has achieved strong customer retention, with a net revenue retention rate of 151% as of December 31, 2024, and boasts high customer satisfaction ratings, positioning itself as a leader in the life sciences validation software market.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
